Skip to main content
Decorative image of the COVID-19 Learning Lounge

Baricitinib Versus Dexamethasone for Adults Hospitalized with COVID-19

SUMMARY

In hospitalized patients with COVID-19 requiring supplemental oxygen, a combination of baricitinib, dexamethasone, and remdesivir resulted in similar survival rates by day 29 compared to the control. However, dexamethasone was associated with significantly more treatment-related adverse events and severe or life-threatening adverse events. bioMérieux Antimicrobial Stewardship Director Katherine Perez, PharmD, participated in this study with the National Institute of Allergy and Infectious Diseases (NIAID). 

FEATURED EXPERT

Katherine Perez, PharmD, Antimicrobial Stewardship Director at bioMérieux


GET STARTED

Read the article at the Lancet.

Read time: 45 minutes


We want to hear from you!

Your feedback helps us continue to provide resources and content specific to your needs.


Global Solutions

BIOMÉRIEUX EPISEQ®

Provides easy-to-use applications for clinical microbiologists: bacterial and fungal identification, clinical pathogen outbreak management, microbiome profiling, and SARS-CoV-2 genomics variants identification.

U.S. bioMérieux Solutions

US Solutions

BIOFIRE® FILMARRAY®

The FILMARRAY is an FDA-cleared multiplex PCR system that integrates sample preparation, amplification, detection and analysis. It requires just a few minutes of hands-on-time and its turnaround time is just about an hour, giving you faster results which may lead to better patient care.

PUBLISHED BY

The Lancet
May 23, 2022


SHARE THIS ARTICLE: